Principal Scientist, Translational PK/PD Modeling
Regeneron Pharmaceuticals
Summary
We are seeking a Principal Scientist of Translational PK/PD Modeling to develop and implement quantitative and mechanistic PK/PD models to aid in the understanding of target biology, therapeutic modality selection/optimization, and contribute to early clinical trial dose selection and/or design and advancement and strategic direction of modeling and simulation sciences.
Job description
Discover Your Role
- Independently develops and implements quantitative and mechanistic mathematical PK/PD models that inform preclinical-to-early clinical translation, including human efficacious dose predictions and first-in-human dose selection.
- Actively contributes to the advancement and strategic direction of modeling and simulation sciences.
- Provides expert support to pre-clinical PK/PD project representatives and R&D project teams to design, execute and interpret in vitro and in vivo quantitative pharmacology studies. This includes working with the Research PK group to optimize use of mouse PK data to inform translation to nonhuman primate and human PK.
- Effectively integrates and summarizes modeling and simulation analyses into useable information for multidisciplinary project teams.
- Remains apprised of emerging science and literature, and effectively collaborates with subject matter experts in Clinical Pharmacology, Quantitative Pharmacology and R&D to advance modeling and simulation sciences.
- Shares learnings and develops best practices across disease areas and therapeutic approaches.
- Committed to sharing technical expertise and the development / mentoring of others.
- Presents work at internal/external scientific meetings and publishes work in scientific journals.
This Role Requires
- Ph.D. and 4+ years of experience, or M.S. and 6+ years of experience in pharmacokinetics, pharmaceutical sciences, engineering, applied mathematics or related disciplines with a track record of applying quantitative and mechanism-based PK/PD modeling and simulation approaches to advance the discovery and development of therapeutics.
- Pharmaceutical industry experience required.
- Experience using one or more modeling and simulation platforms (e.g., Monolix, Phoenix NLME, NONMEN, ADAPT, MATLAB, SimBiology, etc.).
- Strong theoretical and practical foundation in pharmacokinetics, including non-compartmental, compartmental, PK/PD and PBPK.
- Ability to learn new areas of biological sciences to develop quantitative and mechanistic PK/PD models for emerging therapeutic modalities.
- Familiarity with biotherapeutic modalities, including monoclonal and bispecific antibodies, gene therapy, CAR-T, siRNAs and other targeting agents preferred.
Requirements
- Ph.D. and 4+ years of experience, or M.S. and 6+ years of experience in pharmacokinetics, pharmaceutical sciences, engineering, applied mathematics or related disciplines
- Track record of applying quantitative and mechanism-based PK/PD modeling and simulation approaches to advance discovery and development of therapeutics
- Pharmaceutical industry experience required
- Experience using one or more modeling and simulation platforms (e.g., Monolix, Phoenix NLME, NONMEN, ADAPT, MATLAB, SimBiology, etc.)
- Strong theoretical and practical foundation in pharmacokinetics, including non-compartmental, compartmental, PK/PD and PBPK
- Ability to learn new areas of biological sciences to develop quantitative and mechanistic PK/PD models for emerging therapeutic modalities
- Familiarity with biotherapeutic modalities, including monoclonal and bispecific antibodies, gene therapy, CAR-T, siRNAs and other targeting agents preferred
Benefits
- Annual bonuses
- Incentive plans
- Equity awards
- Pension or retirement benefits
- 401(k) company match
- Health and wellness programs
- Fitness centers
- Insurance benefits
- Paid time off
- Family support benefits
Company overview
Regeneron Pharmaceuticals is a leading American biotechnology company founded in 1988 and headquartered in Tarrytown, New York. The company specializes in inventing, developing, and commercializing life-transforming medicines for people with serious diseases. Regeneron is renowned for its innovative antibody technologies and has developed several groundbreaking therapies, including EYLEA® for retinal diseases, DUPIXENT® for inflammatory conditions, and the COVID-19 antibody cocktail REGEN-COV®. The company operates with a strong focus on research and development across multiple therapeutic areas including ophthalmology, oncology, cardiovascular diseases, and rare genetic disorders. Regeneron's proprietary VelocImmune® technology platform enables the rapid generation of fully human monoclonal antibodies. With over 15,000 employees globally and annual revenues exceeding $14 billion, Regeneron has established itself as a major force in the biotechnology industry, consistently ranking among the top-performing pharmaceutical companies and maintaining a robust pipeline of investigational therapies.